Advancing Approaches in Detecting Polymorphism - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Advancing Approaches in Detecting Polymorphism
Identifying polymorphs is a crucial part of the drug-development process as researchers forward select methods to improve detection.

Pharmaceutical Technology

Crystallization in thermodynamic conditions, however, afforded the same product when a proper amount of water was present, points out von Raumer. This product was not hygroscopic, was stable, and its water content determined by KF was about 20%. Crystallization under kinetic conditions, especially when the water activity in the medium was poor, afforded a hygroscopic product with KF lower than 20%. This product was not stable and converted under appropriate conditions into a stable product with KF of approximately 20% and XRPD and Raman results identical with the precipitated product. All the products obtained from crystallization trials that gave KF around 20% displayed the same XRPD spectrum.

"According to the above experiments, it was proven that andolast disodium crystallized in only one preferred hydrated form: the penthaydrate. All other hydrated forms were not stable and converted under appropriate conditions into the pentahydrate," notes von Raumer. "The single-crystal structure was resolved, and molecular-mechanics simulation showed that, upon water removal, a certain degree of distortion was introduced within the crystal structure, with the distortion being proportional to the number of water molecules removed."

From this solid-state study, a new crystalline form, andolast pentahydrate, was revealed, which displayed certain superior properties, says von Raumer. Andolast pentahydrate is not a hygroscopic solid, is stable to mechanical milling, and is stable to as much as 85% relative humidity. It also can consistently be prepared according to a standard process, has constant mechanical properties such as flowability, and has advantages in formulation in comparison with previous material because of a better performance in delivered dose, fine particles delivered, and fine-particle fraction. Aside from improved performance, the new crystalline form of andolast also led to patent applications in the United States and Europe (13, 14). The European patent application calls for an expiration date of 2026 compared with the original expiration date of 2010 that is specified in an earlier patent (15).

"While the development of the andolast drug product was hampered due to inconsistencies and was slowed down by a non-negligible factor, the actual situation allows for a rapid continuation with a possibly much longer time horizon of exclusivity," says von Raumer. "This situation once again demonstrates the utility and opportunities that are created by carefully investigating the solid-state aspects of drug candidates."

Analytical methods for polymorphs

XRPD is the most common analytical method used in polymorph screening, although certain researchers use Raman spectroscopy as their primary screening method. "Each method has its value, and more recently SAFC-Pharmorphix has been experimenting on the use of both methods in combination for polymorph and cocrystal screening using a combined X-ray powder diffractometer with a Raman attachment," says Frampton. "This instrument has been developed in collaboration with Bruker AXS, and a patent covering this technology has recently been published (16). This technology has been further enhanced by a new release of the clustering program, Polysnap2, which can cluster any two-dimensional data and produce weighted combinations." SAFC-Pharmorphix has an active collaboration with Professor Chris Gilmore and his group at the University of Glasgow (Glasgow, UK).

In a typical study, a crystallographer places a compound in a range of solvents and subjects them to a range of crystallization conditions in hopes of obtaining single crystals, Aptuit's Byrn explains. He points out that the number of solvents used in the screening varies. A small polymorph screen should include 8–10 solvents (17). "A more complete screen would require more than 50 solvents," he adds. In recent research, Xu and Redman-Furey outlined an approach to narrow their selection of 57 solvents to 20 (18). Byrn points out that in a related study, Miller suggested an approach of finding the most stable polymorphs by slurring compounds in a variety of solvents (19).

"We now know that solvent-based crystallizations alone do not find all of the forms. In several cases, solvent-based polymorph screens have missed very important solid forms," explains Byrn. In another example, Yu discovered the second most stable form of 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile (ROY) using a melt-recrystallization technique (20). "It is well established that ROY had previously been screened by all of the best-known high-throughput techniques, and this form had not been found," explains Byrn, adding, solvent-free techniques such as drying, sublimation, and amorphous crystallization can produce new forms not discovered by solvent-based crystallization.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here